SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.

doi:10.1158/1078-0432.CCR-18-0937

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2018

Boysen Gunther, Rodrigues Daniel N, Rescigno Pasquale, Seed George, Dolling David, Riisnaes Ruth, Crespo Mateus, Zafeiriou Zafeiris, Sumanasuriya Semini, Bianchini Diletta, Hunt Joanne, Moloney Deirdre, Perez-Lopez Raquel, Tunariu Nina, Miranda Susana, Figueiredo Inês, Ferreira Ana, Christova Rossitza, Gil Veronica, Aziz Sara, Bertan Claudia, de Oliveira Flavia M, Atkin Mark, Clarke Matthew, Goodall Jane, Sharp Adam, MacDonald Theresa, Rubin Mark A, Yuan Wei, Barbieri Christopher E, Carreira Suzanne, Mateo Joaquin, de Bono Johann S

Abstract excerpt

Purpose: CHD1 deletions and SPOP mutations frequently cooccur in prostate cancer with lower frequencies reported in castration-resistant prostate cancer (CRPC). We monitored CHD1 expression during disease progression and assessed the molecular and clinical characteristics of CHD1-deleted/SPOP-mutated metastatic CRPC (mCRPC).Experimental Design: We identified 89 patients with mCRPC who had hormone-naive and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androstenes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Helicases

Share to Drug Resistance, Neoplasm

Share to Neoplasm Grading

Share to Neoplasm Staging

Share to Prostatic Neoplasms

Share to RNA, Small Interfering

Share to Synthetic Lethal Mutations

Source

Open in PubMed Open full text

Identifiers

PMID: 30068710
DOI: 10.1158/1078-0432.CCR-18-0937
PMCID: PMC6830304

Genes

CHD1
SPOP
ERG
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.PMID 30068710Read ↗

SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.Semantic proximity Read ↗

CHD1 loss reprograms SREBP2-driven cholesterol synthesis to fuel androgen-responsive growth and castration resistance in SPOP-mutated prostate tumors.Semantic proximity Read ↗

Clinical and genomic features of SPOP‐mutant prostate cancerSemantic proximity Read ↗

CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair.Semantic proximity Read ↗

SPOP mutation leads to genomic instability in prostate cancerSemantic proximity Read ↗

Divergent roles of SPOP and CHD1 in ACSL4 regulation reveal context-dependent vulnerabilities for targeting ferroptosis.Semantic proximity Read ↗

Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancerSemantic proximity Read ↗

CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.Semantic proximity Read ↗

SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.Semantic proximity Read ↗

SPOP-mutant prostate cancer: Translating fundamental biology into patient care.Semantic proximity Read ↗

Outcomes for Patients With SPOP Mutated Castration-Resistant Prostate Cancer (CRPC) Treated With an Androgen Receptor Pathway Inhibitor (ARPI).Semantic proximity Read ↗

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.